• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

GEMFIBROZIL Drug Record

  • Summary
  • Interactions
  • Claims
  • GEMFIBROZIL chembl:CHEMBL457 Approved

    Alternate Names:

    LOPID
    CI-719
    GEMFIBROZIL
    EMFIB
    GEMFIBROZILUM
    GEMFIBROZILO
    2,2-DIMETHYL-5-(2,5-DIMETHYLPHENOXY)VALERIANSAEURE
    2,2-DIMETHYL-5-(2,5-XYLYLOXY)VALERIANSAEURE
    2,2-DIMETHYL-5-(2,5-XYLYLOXY)VALERIC ACID
    JEZIL®
    GEN-FIBRO®
    chembl:CHEMBL457
    pubchem.compound:3463
    chemidplus:25812-30-0
    drugbank:01241
    rxcui:4719

    Drug Info:

    Drug Class antilipemic agents
    Year of Approval 1981
    FDA Approval 1981
    Drug Class small molecule
    Drug Indications Antilipemic Agents
    (4 More Sources)

    Publications:

    Goto et al., 1997, Upregulation of low density lipoprotein receptor by gemfibrozil, a hypolipidemic agent, in human hepatoma cells through stabilization of mRNA transcripts., Arterioscler. Thromb. Vasc. Biol.
    Yamazaki et al., 2005, Effects of fibrates on human organic anion-transporting polypeptide 1B1-, multidrug resistance protein 2- and P-glycoprotein-mediated transport., Xenobiotica
    Varma MV et al., 2015, Quantitative Rationalization of Gemfibrozil Drug Interactions: Consideration of Transporters-Enzyme Interplay and the Role of Circulating Metabolite Gemfibrozil 1-O-β-Glucuronide., Drug Metab Dispos
    Sharma P et al., 2010, Validation of cell-based OATP1B1 assays to assess drug transport and the potential for drug-drug interaction to support regulatory submissions., Xenobiotica
    Roy et al., 2007, Myelin basic protein-primed T cells induce neurotrophins in glial cells via alphavbeta3 [corrected] integrin., J. Biol. Chem.
    Pahan et al., 2002, Gemfibrozil, a lipid-lowering drug, inhibits the induction of nitric-oxide synthase in human astrocytes., J. Biol. Chem.
    Shoji et al., 2003, Preparation of antiserum against rat delta6-desaturase and its use to evaluate the desaturase protein levels in rats treated with gemfibrozil, a ligand for peroxisome proliferator-activated receptor alpha., Biosci. Biotechnol. Biochem.
    Clavey et al., 1999, Cell culture conditions determine apolipoprotein CIII secretion and regulation by fibrates in human hepatoma HepG2 cells., Cell. Physiol. Biochem.
    Bossé et al., Influences of the PPAR alpha-L162V polymorphism on plasma HDL(2)-cholesterol response of abdominally obese men treated with gemfibrozil., Genet. Med.
    Rizvi et al., 2003, Beneficial effects of fish liver preparations of sea bass (Lates calcarifer) versus gemfibrozil in high fat diet-induced lipid-intolerant rats., J Med Food
    De Filippis et al., 2011, Discovery of gemfibrozil analogues that activate PPARα and enhance the expression of gene CPT1A involved in fatty acids catabolism., Eur J Med Chem
    Törüner et al., 2004, Effects of PPARgamma and PPARalpha agonists on serum leptin levels in diet-induced obese rats., Horm. Metab. Res.
    Hung et al., 1999, Effects of lovastatin and gemfibrozil in subjects with high ratios of total cholesterol to high-density lipoprotein cholesterol., J. Formos. Med. Assoc.
    MacDonald ML et al., 2006, Identifying off-target effects and hidden phenotypes of drugs in human cells., Nat Chem Biol
    Irish et al., 1996, The effects of gemfibrozil upon the hypercoagulable state in dyslipidaemic patients with chronic renal failure., Nephrol. Dial. Transplant.
    Bossé Y et al., 2002, Influence of the angiotensin-converting enzyme gene insertion/deletion polymorphism on lipoprotein/lipid response to gemfibrozil., Clin Genet
  • GEMFIBROZIL   LEP

    Interaction Score: 1.24

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15114521 10083765


    Sources:
    NCI

  • GEMFIBROZIL   PPARA

    Interaction Score: 1.08

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Mechanism of Interaction Peroxisome proliferator-activated receptor alpha agonist
    Direct Interaction yes
    Trial Name -

    PMIDs:
    12244038 12834305 10494028 12172398 12935323 21889235


    Sources:
    DTC TdgClinicalTrial ChemblInteractions TEND

  • GEMFIBROZIL   LDLR

    Interaction Score: 0.59

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9409246


    Sources:
    NCI

  • GEMFIBROZIL   IL6

    Interaction Score: 0.49

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8941582


    Sources:
    NCI

  • GEMFIBROZIL   SLCO1B1

    Interaction Score: 0.48

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    16316932 25941268 19919292


    Sources:
    NCI

  • GEMFIBROZIL   LPL

    Interaction Score: 0.34

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • GEMFIBROZIL   JUN

    Interaction Score: 0.28

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16680159


    Sources:
    DTC

  • GEMFIBROZIL   ACE

    Interaction Score: 0.22

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12123487


    Sources:
    PharmGKB

  • GEMFIBROZIL   BDNF

    Interaction Score: 0.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17823123


    Sources:
    NCI

  • GEMFIBROZIL   CYP2C9

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TEND: GEMFIBROZIL

    • Version: 01-August-2011

    Alternate Names:
    GEMFIBROZIL Primary Drug Name

    Drug Info:
    Year of Approval 1981
    Drug Class antilipemic agents

    Publications:

  • TdgClinicalTrial: GEMFIBROZIL

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications Antilipemic Agents
    Drug Class small molecule
    FDA Approval 1981

    Publications:

  • NCI: GEMFIBROZIL

    • Version: 14-September-2017

    Alternate Names:
    C29071 NCI drug code

    Drug Info:

    Publications:
    Irish et al., 1996, The effects of gemfibrozil upon the hypercoagulable state in dyslipidaemic patients with chronic renal failure., Nephrol. Dial. Transplant.
    Goto et al., 1997, Upregulation of low density lipoprotein receptor by gemfibrozil, a hypolipidemic agent, in human hepatoma cells through stabilization of mRNA transcripts., Arterioscler. Thromb. Vasc. Biol.
    Hung et al., 1999, Effects of lovastatin and gemfibrozil in subjects with high ratios of total cholesterol to high-density lipoprotein cholesterol., J. Formos. Med. Assoc.

  • DTC: GEMFIBROZIL

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL457 ChEMBL Drug ID

    Drug Info:

    Publications:
    MacDonald ML et al., 2006, Identifying off-target effects and hidden phenotypes of drugs in human cells., Nat Chem Biol
    De Filippis et al., 2011, Discovery of gemfibrozil analogues that activate PPARα and enhance the expression of gene CPT1A involved in fatty acids catabolism., Eur J Med Chem

  • PharmGKB: gemfibrozil

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Bossé Y et al., 2002, Influence of the angiotensin-converting enzyme gene insertion/deletion polymorphism on lipoprotein/lipid response to gemfibrozil., Clin Genet

  • TTD: Gemfibrozil

    • Version: 2020.06.01

    Alternate Names:
    D05VIX TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL457

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL457

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21